Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily CSI China Internet Bull 2X Shares vs Smith & Nephew plc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $22.3, while Smith & Nephew plc trades at $30.06 (market cap $12.40B). The key difference: Smith & Nephew plc pays a 2.62% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none. Which is the better fit depends on your goals.
| CWEB | SNN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $60.13 | $38.70 |
52-Week Low | $17.70 | $28.73 |
Market Cap | — | $12.40B |
Enterprise Value | — | $15.17B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $21.61, down 1.46% today, with technical indicators showing a bullish bias from moving averages but a neutral stance from oscillators. The stock lacks recent fundamental data, with key valuation and profitability ratios unavailable. A dividend of $0.09 is scheduled for June 2026, indicating a potential income component.
The outlook is mixed due to incomplete financials; technical strength offers near-term upside potential, but investment decisions require updated earnings and revenue figures. Risks include data gaps and market volatility, warranting caution until fundamental clarity emerges from SEC filings or company announcements.
SNN trades at $31.08, up 1.24% with a bullish technical signal. The company shows improving fundamentals with 2024 revenue of $5.81B and net income of $412M, while recent earnings beat expectations. Strong cash flow generation and new product launches in robotics and wound care support growth. Analyst consensus is mixed with 27% buy ratings but majority holds.
Outlook remains positive with projected revenue growth and margin expansion, though recent earnings misses and elevated valuation metrics pose risks. The stock's technical strength and fundamental recovery present opportunity, but investor caution is warranted given mixed analyst sentiment and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
